Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Canada Supreme Court Won’t Hear Eli Lilly Zyprexa Appeal

May 16 (Bloomberg) -- Canada’s Supreme Court dismissed Eli Lilly & Co.’s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.

The country’s highest court said in a statement today it decided not to look at the case after hearing from parties involved in the matter earlier this week. A Federal Court in 2011 ruled the patent was invalid because it did not meet “utility” requirements.

The Indianapolis-based firm has claimed recent decisions by Canadian courts invalidating 17 drug patents over “utility” requirements have made the country an outlier among major developed countries, prompting the company in December to notify Canada of its plans to file a trade complaint over its patent for its Strattera drug.

“Addressing Canada’s outlier status with respect to the interpretation of patent law is a priority for Lilly,” the company said in a statement today. “We will continue to consider all our legal options to protect what we believe to be valid intellectual property rights protecting our patents in Canada.”

To contact the reporter on this story: Theophilos Argitis in Ottawa at targitis@bloomberg.net

To contact the editor responsible for this story: David Scanlan at dscanlan@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.